Severity and impact of xerostomia in patients treated with botulinum toxin type b for cervical dystonia: Observations on the quality of life of patients with xerostomia

Current Therapeutic Research - Clinical and Experimental

Volumn 65, Issue 2, 2004, Pages 161-171

  Hogan, Patrick ^a   Charles, P David ^b   Wooten Watts, Maureen ^c   Massey, Janice M ^d   Miller, Tamara ^e   Mackowiack, John ^f  

^a Tacoma Neurological Associates   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Neurology Specialists of Dallas   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Advanced Neurology of Colorado LLC   (United States)

^f Center for Outcomes Research   (United States)

Author keywords

botulinum toxin; patient benefit questionnaire; xerostomia

Indexed keywords

EID: 33745968189     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(04)90030-6     Document Type: Article

References (25)

1. Lang A.E., Sheehy M.P., and Marsden C.D. Acute anti-cholinergic action in focal dystonia. Adv Neurol 37 (1983) 193-200
2. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 33 (1983) 1255-1261
3. Tsui J.K., Eisen A., Stoessl A.J., et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2 (1986) 245-247
4. Naumann M., Yakovleff A., Durif F., and BOTOX Cervical Dystonia Prospective Study Group. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 249 (2002) 57-63
5. Brans J.W., Lindeboom R., Snoek J.W., et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial. Neurology 46 (1996) 1066-1072
6. Brin M.F., Lew M.F., Adler C.H., et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53 (1999) 1431-1438
7. Brashear A., Lew M.F., Dykstra D.D., et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53 (1999) 1439-1446
8. Dressler D., and Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49 (2003) 34-38
9. Dressler D. Dysport produces intrinsically more swallowing problems than Botox: Unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry 73 (2002) 604
10. Dodel R.C., Kirchner A., Koehne-Volland R., et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmaco Economics 12 (1997) 695-706
11. Lew M.F., Adornato B.T., Duane D.D., et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49 (1997) 701-707
12. MYOBLOC®/NEUROBLOC® (botulinum toxin type B) [package insert]. South San Francisco, Calif; Elan Pharmaceuticals, Inc: 2000.
13. Jahanshahi M., Marion M.H., and Marsden C.D. Natural history of adult-onset idiopathic torticollis. Arch Neurol 47 (1990) 548-552
14. Van Zandijcke M. Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. Acta Neurol Belg 95 (1995) 210-215
15. Eisbruch A., Kim H.M., Terrell J.E., et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 695-704
16. Couffignal A.L., Lemozit J.P., Bahgeri H., et al. Influence of medications on salivary flow and dental caries. Meth Find Exp Clin Pharmacol 18 Suppl B (1996) 206 Abstract
17. Melvin J.E. Saliva and dental diseases. Curr Opin Dent 1 (1991) 795-801
18. Mandel I.D. Oral defenses and disease: Salivary gland function. Gerodontology 3 (1984) 47-54
19. Horiot J.C., Lipinski F., Schraub S., et al. Post-radiation severe xerostomia relieved by pilocarpine: A prospective French cooperative study. Radiother Oncol 55 (2000) 233-239
20. Nusair S., and Rubinow A. The use of oral pilocarpine in xerostomia and Sjögren's syndrome. Semin Arthritis Rheum 28 (1999) 360-367
21. Mendes R.L., Nutting C.M., and Harrington K.J. Managing side effects of radiotherapy in head and neck cancer. Hosp Med 63 (2002) 712-717
22. Bjordal K., Kaasa S., and Mastekaasa A. Quality of life in patients treated for head and neck cancer: A follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oacol Biol Phys 28 (1994) 847-856
23. Wasserman T., Mackowiak J.I., Brizel D.M., et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 48 (2000) 1035-1039
24. Brashear A., McAfee A.L., Kuhn E.R., and Ambrosius W.T. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil 84 (2003) 103-107
25. Opida C.L. Open-label study of Myobloc (botulinum toxin type B) in the treatment of post-whiplash headaches. Arch Pharmacol 385 Suppl 2 (2002) R32 96. Abstract